Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Krystexxa Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Krystexxa (pegloticase) Coverage Criteria

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    HMSA Medicare Advantage coverage and prior authorization for Krystexxa in adults with chronic gout refractory to conventional therapy, including initial and continuation requirements.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyKrystexxa (pegloticase) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJune 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionPrecertification is required for Krystexxa; providers should use the applicable HMSA medical policy fax form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    < 6 mg/dLSerum uric acid response
    2 consecutiveElevated uric acid limit
    2+/yearFrequent gout flares
    Adult chronic gout

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered indication

    Coverage Criteria

    Initial therapy for chronic gout

    Authorization of 12 months may be granted for chronic gout when ALL of the following criteria are met:

    Initial therapy

    • Required initial-therapy criteria

      • No concomitant oral urate-lowering therapy: The requested medication will NOT be used concomitantly with oral urate-lowering therapies.
      • Conventional therapy failure or avoidance

        • Refractory to conventional therapy: The member is refractory to conventional therapy, such as allopurinol or febuxostat, at the maximum medically appropriate dose.
        • Clinical reason to avoid conventional therapy: The member has a clinical reason to avoid treatment with all conventional therapies.
      • Methotrexate pathway

        • Methotrexate coadministration: The requested medication will be co-administered with weekly oral methotrexate and folic acid or folinic acid supplementation.
        • Methotrexate avoidance: The member has a contraindication to or clinical reason to avoid oral methotrexate therapy.

    Continuation therapy and reauthorization

    Authorization of 12 months may be granted for continuation therapy when ALL of the following criteria are met:

    • Current treatment and covered indication: The member is currently receiving therapy with the requested medication, and the requested medication is being used to treat an indication in the coverage criteria section.
    • Serum uric acid requirement: The member has NOT had two consecutive serum uric acid levels above 6 mg/dL since starting treatment with the requested medication.Not two consecutive levels > 6 mg/dL
    • Clinical benefit: The member is receiving benefit from therapy, such as serum uric acid levels < 6 mg/dL, reduction of tophi, or reduction of symptoms and/or flares.Serum uric acid < 6 mg/dL is an example of benefit.

    Krystexxa is not recommended for treatment of asymptomatic hyperuricemia. This condition is excluded from the covered indication.

    For initial authorization, Krystexxa may not be used concomitantly with oral urate-lowering therapies.

    Clinical Thresholds and Limits

    Serum uric acid response
    Response thresholdSerum uric acid levels < 6 mg/dL
    DocumentationContinuation submissions may include laboratory results demonstrating serum uric acid levels < 6 mg/dL
    Clinical benefitSerum uric acid levels < 6 mg/dL are an example of benefit from therapy
    Serum uric acid continuation limit
    Continuation limitThe member must not have two consecutive serum uric acid levels above 6 mg/dL
    Measurement periodThe assessment applies since starting treatment with the requested medication
    Reauthorization impact

    Authorization and Documentation Requirements

    Prior Authorization

    Precertification Required

    Precertification is required for Krystexxa submissions. Refer to the HMSA medical policy website for the applicable fax form.

    Step Therapy

    Failure or Intolerance of Conventional Therapy

    Initial authorization for chronic gout requires documentation that the member is refractory to conventional urate-lowering therapy, such as allopurinol or febuxostat, or has a clinical reason to avoid all conventional therapies.

    • Examples of conventional therapy include allopurinol and febuxostat.
    • Krystexxa is not recommended as initial first-line urate-lowering therapy.

    Policy Background

    Krystexxa (pegloticase) is indicated for the treatment of chronic gout in adults who are refractory to conventional therapy. Refractory disease may involve failure to respond to conventional treatment, such as allopurinol or febuxostat, at the maximum medically appropriate dose, or a clinical reason to avoid conventional therapies. Krystexxa is not recommended for asymptomatic hyperuricemia.

    Key Definitions

    Chronic gout refractory to conventional therapy
    ConditionChronic gout refractory to conventional therapy
    Patient populationAdult patient
    DefinitionGout that persists despite conventional therapy
    Refractory to conventional therapy
    MeaningFailure to respond to conventional therapy
    Examples of conventional therapyAllopurinol or febuxostat
    Qualifying circumstancesFailure at the maximum medically appropriate dose, or a clinical reason to avoid treatment with all conventional therapies

    Initial Therapy Criteria

    Initial therapy for chronic gout

    Authorization of 12 months may be granted for treatment of chronic gout when ALL of the following criteria are met:

    Initial Krystexxa therapy

    • No concomitant oral urate-lowering therapy: The requested medication will NOT be used concomitantly with oral urate-lowering therapies.
    • Conventional therapy failure or avoidance

      • Refractory to conventional therapy: The member is refractory to conventional therapy (e.g., allopurinol, febuxostat) at the maximum medically appropriate dose.
      • Clinical reason to avoid conventional therapy: The member has a clinical reason to avoid treatment with all conventional therapies.

    Continuation Criteria

    Krystexxa continuation

    Authorization for 12 months may be granted when ALL of the following continuation criteria are met:

    • Current therapy: The member is currently receiving therapy with Krystexxa.
    • Covered indication: Krystexxa is being used to treat an indication in the coverage criteria section.
    • Serum uric acid requirement: The member has NOT had two consecutive serum uric acid levels above 6 mg/dL since starting treatment with Krystexxa.Not two consecutive levels > 6 mg/dL

    Step Therapy

    StepRequirementQualification criteria
    1Try and fail or be unable to use conventional urate-lowering therapy before Krystexxa.The member must be refractory to conventional therapy, such as allopurinol or febuxostat, at the maximum medically appropriate dose, or have a clinical reason to avoid treatment with all conventional therapies.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyKrystexxa (pegloticase) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJune 26, 2026
    Last ReviewMar 1, 2026
    Next Review DateN/A
    Key ActionPrecertification is required for Krystexxa; providers should use the applicable HMSA medical policy fax form.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and LimitsAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy
    Two consecutive serum uric acid levels above 6 mg/dL do not meet the continuation criterion
    Frequent gout flares
    Frequent flare threshold2 or more gout flares per year
    Lower flare frequencyFewer than 2 gout flares per year is considered infrequent
    Treatment rationaleFrequent flares of 2 or more per year may support switching to Krystexxa when other interventions have failed to achieve serum urate targets
    Documentation Required

    Document Response for Continuation

    For continuation submissions, maintain documentation demonstrating response to therapy, such as chart notes and laboratory results. Examples include serum uric acid below 6 mg/dL, reduced tophi, or reduced symptoms and/or flares.

    • Include relevant chart notes and lab test results with continuation requests.
    Documentation Required

    Other Indications Require Compendial Support

    Requests for indications other than those listed in the coverage criteria are assessed individually and must include supporting evidence from Medicare-approved compendia.

    • Submit compendial support for other indications.
    Denial Risk

    Asymptomatic Hyperuricemia Excluded

    Krystexxa is not recommended for the treatment of asymptomatic hyperuricemia; treatment for this condition is outside the covered indication.

    Denial Risk

    Do Not Use Concomitantly With Oral Urate-Lowering Therapy

    For initial chronic gout authorization, Krystexxa must not be used concomitantly with oral urate-lowering therapies. Requests specifying concomitant oral urate-lowering therapy may be denied.

    Step Therapy

    Conventional Therapy Requirement

    Document that the member is refractory to conventional therapy at the maximum medically appropriate dose, or provide the clinical reason to avoid treatment with all conventional therapies.

    • Conventional therapy examples include allopurinol and febuxostat.
    Prior Authorization

    Methotrexate and Supplementation Requirement

    For chronic gout, document that Krystexxa will be co-administered with weekly oral methotrexate and folic acid or folinic acid supplementation, unless the member has a contraindication to or clinical reason to avoid oral methotrexate therapy.

    • Required regimen: weekly oral methotrexate plus folic acid or folinic acid supplementation.
    • An applicable contraindication or clinical reason to avoid oral methotrexate may satisfy the exception.
    Denial Risk

    Continuation Criteria Must Be Met

    Continuation authorization may be denied when the member is not currently receiving the requested medication, the medication is not being used for an indication in the coverage criteria, or the member has had two consecutive serum uric acid levels above 6 mg/dL since starting therapy. Members without a previous authorization or precertification must meet the initial approval criteria.

    • Continuation authorization also requires that the member be receiving benefit from therapy.
    • Authorization is available only when all continuation criteria are met.
    Two consecutive elevated serum uric acid levels
    DefinitionA serum uric acid result greater than 6 mg/dL occurring twice consecutively
    TimingThe results must occur since initiation of Krystexxa
    Continuation criterionThe member must not have two consecutive serum uric acid levels above 6 mg/dL since starting treatment
  1. Methotrexate pathway

    • Methotrexate coadministration: The requested medication will be co-administered with weekly oral methotrexate and folic acid or folinic acid supplementation.
    • Methotrexate avoidance: The member has a contraindication to or clinical reason to avoid oral methotrexate therapy.
  2. Clinical benefit:
    The member is receiving benefit from therapy, such as serum uric acid levels < 6 mg/dL, reduction of tophi, or reduction of symptoms and/or flares.
    Serum uric acid < 6 mg/dL is an example of benefit.